Browse > Article
http://dx.doi.org/10.7314/APJCP.2014.15.21.9479

Methylation Status and Immunohistochemistry of BRCA1 in Epithelial Ovarian Cancer  

Pradjatmo, Heru (Department of Obstetric and Gynecology, Faculty of Medicine, Universitas Gadjah Mada)
Dasuki, Djaswadi (Department of Obstetric and Gynecology, Faculty of Medicine, Universitas Gadjah Mada)
Anwar, Mohammad (Department of Obstetric and Gynecology, Faculty of Medicine, Universitas Gadjah Mada)
Mubarika, Sofia (Department of Histology and Biomolecular, Faculty of Medicine, Universitas Gadjah Mada)
Harijadi, Harijadi (Department of Pathology, Faculty of Medicine, Universitas Gadjah Mada)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.15, no.21, 2014 , pp. 9479-9485 More about this Journal
Abstract
Background: Cancer initiation and progression are controlled by genetic and epigenetic events. One epigenetic process which is widely known is DNA methylation, a cause of gene silencing. If a gene is silenced the protein which it encodes will not expressed. Objectives: 1. Identify the methylation status of BRCA1 in patients with epithelial ovarian cancer (EOC)and assess BRCA1 protein expression in tumor tissue. 2. Examine whether BRCA1 gene methylation and BRCA1 protein are associated with survival of epithelial ovarian cancer patients. Methods: The study design was a prospective-cohort study, conducted at Sardjito hospital, Yogyakarta, Indonesia. Results: A total of 69 cases were analyzed in this study. The data showed that the methylation status of BRCA1 in EOC was positive in 89.9%, with clear protein expression of BRCA1 in 31.9%. Methylation status and expression of BRCA1 were not prognosticators of EOC patients. Menarche, CA125 level, clinical stage and residual tumor were independent factors for prognosis.
Keywords
EOC; methylation; BRCA1; prognosis factors; survival;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
연도 인용수 순위
1 Bai X, Fu, Y, Xue, H, et al (2014). BRCA1 promoter methylation in sporadic epithelal ovarian carsinoma: Association with low expression of BRCA1, improved survival and coexpression of DNA methyltransferases. Oncol Letters, 7, 1088-96.
2 Bast Jr RC, Ravdin P, Hayes DF, et al (2000). Update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American society of clinical oncology. J Clin Oncol, 19, 1865-78.
3 Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Monntz FJl (2002). Suvival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol, 20, 1248-59.   DOI   ScienceOn
4 Chan JK, Urban R, Cheung MK, et al (2006). Ovarian cancer in younger vs older women: a population-based analysis. Br J Cancer, 95, 1314-20.   DOI
5 Chiang JW, Karlan BY, Cass I, Baldwin RL (2006). BRCA1 promoter methylation predicts adverse ovarian cancer prognosis. Gynecol Oncol, 101, 403-10.   DOI   ScienceOn
6 Duska LR, Chang YC, Flynn CE, et al (1999). Epithelial ovarian carcinoma in the reproductive age group. Cancer, 85, 2623-9.   DOI   ScienceOn
7 Elstrand MB, Sandstad B, Oksefjell H, Davidson B, Trope CG (2012). Prognostic significance of residual tumor in patients with epithelial ovarian carcinoma stage IV in a 20 years perspective. Acta Obstet Gynecol Scan, 91, 308-17.   DOI
8 Esteller M, Corn PG, Baylin, SB (2001). Herman JG. A gene hypermethylation profile of human cancer. Cancer Res, 61, 3225-9.
9 Esteller M, Sanchez-Cespedes M, Rosell R, et al (1999). Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res, 59, 67-70.
10 Hahn WC, Weinberg RA (2002). Rules for making human tumor cells. N Engl J Med, 347, 1593-603.   DOI   ScienceOn
11 Heo I, Joo C, Cho J (2008). Lin28 mediate terminal undylation of let-7 precursur microRNA. Mol Cell, 32, 276-8.   DOI   ScienceOn
12 Hilton JL, Geisler JP, Rathe JA, et al (2002). Inactivation of BRCA1 and BRCA2 in Ovarian Cancer. J Natl Cancer Inst, 94, 1396-406.   DOI
13 Hoffman BL, Schorge JO, Schaffer JL, et al (2012). Epithelial Ovarian Cancer. In Williams Gynecology, 2nd Ed, Mc Graw Hill Co, 853-78.
14 Kawahara N, Nishikura K (2009). Regulation of the miRNA function by RNA editing. Tanpakushitsu Kakusan Koso, 54, 1133-40.
15 Hogdall EV, Christensen L, Kjaer SK, et al (2007). CA 125 expression pattern, prognosis and correlation with serum CA 125 in ovarian tumor patients from the Danish "Malova" ovarian cancer study. Gynecol Oncol, 104, 508-17.   DOI   ScienceOn
16 Issa J-P J, Kantarjian HM, Kirkpatrick P (2005). Fresh from the pipeline azacitidine. Nat Rev, 4, 275-6.
17 Jacobs I, Bast RC (1989). The CA125 tumour-associated antigen: a review of the literature. Human Reprod, 4, 1-12.   DOI
18 Laird PW (2003). The power and the promise of DNA methylation markers. Nat Rev Cancer, 3, 253-66.   DOI   ScienceOn
19 Lan VTT, Thuan TB, Thu DM, et al (2013). Methylation profile of BRCA1, RASSF1A and ER in Vietnamese women with Ovarian Cancer. Asian Pac J Cancer Prev, 14, 7713-8.   과학기술학회마을   DOI   ScienceOn
20 Massi D, Susini T, Savino L, et al (1996). Epithelial ovarian tumors in the reproductive age group: age is not an independent prognostic factor. Cancer, 77, 1131-36..   DOI   ScienceOn
21 Landis SH, Murray T, Bolden S, Wingo P (1998). Cancer statistics. CA Cancer J Clin, 48, 6-30.   DOI   ScienceOn
22 Lesnock JL, Darcy KM, Tian C, et al (2013). BRCA1 expression and improved survival in ovarian cancer patients treated with intaperitoneal cisplatin and paclitaxel: a gynecologic oncology group study. Br J Cancer, 108, 1231-37.   DOI   ScienceOn
23 Nagele F, Petru E, Medl M, et al (1995). Preoperative CA 125: an independent prognostic factor in patients with stage I epithelial ovarian cancer. Obstet Gynecol, 86, 259-64.   DOI   ScienceOn
24 Li C, Feng Y, Coukos G, Zhang L (2011). MicroRNAs in epithelial ovarian cancer. In William CS Cho Editor. in MicroRNAs in Cancer Translational Research. Springer Science, 309-42
25 Montavon C, Gloss BS, Warton K, et al (2012). Prognostic and diagnostic significance of DNA methylation patterns in high grade serous ovarian cancer. Gynecol Oncol, 124, 582-88.   DOI   ScienceOn
26 Munkarah AR, Hallum AV, Morris M, et al (1997). Prognostic significance of residual disease in patients with stage IV epithelial ovarian cancer. Gynecol Oncol, 64, 13-7.   DOI   ScienceOn
27 Paramasivam S, Tripcony L, Crandon A, et al (2005). Prognostic importance of preoperative CA-125 in international federation of gynecology and obstetrics stage I epithelial ovarian ancer: an Australian multicenter study. J Clin Oncol, 23, 1-5.   DOI   ScienceOn
28 Petri AL, Hogdall EV, Christensen IBJ, et al (2006). Preoprative CA125 as a prognostic factor in stage I epithelial ovarian cancer. APMIS, 114, 358-63.
29 Rodriguez M, Nguyen HN, Averette HE, et al (1994). National survey of ovarian carcinoma XII. Epithelial ovarian malignancies in women less than or equal to 25 years of age. Cancer, 73, 1245-50.   DOI   ScienceOn
30 Saeed S, Akram, M (2012). Epithelial ovarian cancer: epidemiology and clinicopathological features. Profesional Med J, 19, 1040-5.
31 Urban N (2003). Specific keynote: Ovarian cancer risk assessment and the potential for early detection. Gynecol Oncol, 88, 75-9.   DOI   ScienceOn
32 Segelman J, Floter-Radestad A, Hellborg H. Sjovall A, Martling A (2010). Epidemiology and prognosis of ovarian metastases in colorectal cancer. Br J Surg, 97, 1704-9.   DOI
33 Shawky AEA, El-Hafez AA, El-Tantawy, Hamdy R (2014). No association between BRCA1 immunohistochemical expression and tumor grade, stage or overall survival in platinum-tested epithelial ovarian cancer patients. Asian Pac J Cancer Prev, 15, 4275-9.   과학기술학회마을   DOI
34 Thrall M, Gallion, HH, Kryscioz R, et al (2006). BRCA1 expression in a large series of sporadic ovarian carcinomas: a Gynecologic Oncology Group study. Int J Gynecol Cancer, 16, 166-71.   DOI
35 Winter III WE, Maxwell GL, Tian C, et al (2008). Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a gynecologic oncology group study. J Clin Oncol, 26, 83-9.   DOI   ScienceOn
36 Yang D, Khan S, Sun Y, et al (2011). Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA, 306, 1557-65.   DOI   ScienceOn